Volume 20, Issue 1, Pages (January 2017)

Slides:



Advertisements
Similar presentations
Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where Jennifer B. McCormick, Jason Owen-Smith, Christopher Thomas Scott Cell Stem Cell.
Advertisements

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.
Module Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem Cells David J. Wong, Helen Liu, Todd W. Ridky, David Cassarino, Eran Segal, Howard.
IPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening Mahendra Rao Cell Stem Cell Volume 13, Issue 4, Pages (October.
Fate Restriction and Multipotency in Retinal Stem Cells Lázaro Centanin, Burkhard Hoeckendorf, Joachim Wittbrodt Cell Stem Cell Volume 9, Issue 6, Pages.
Myc Represses Primitive Endoderm Differentiation in Pluripotent Stem Cells Keriayn N. Smith, Amar M. Singh, Stephen Dalton Cell Stem Cell Volume 7, Issue.
Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities Koen Schepers, Timothy B. Campbell, Emmanuelle Passegué Cell Stem Cell Volume.
Quantitative Single-Cell Approaches to Stem Cell Research Martin Etzrodt, Max Endele, Timm Schroeder Cell Stem Cell Volume 15, Issue 5, Pages (November.
Kevin G. Chen, Barbara S. Mallon, Ronald D.G. McKay, Pamela G. Robey 
The Principles of Engineering Immune Cells to Treat Cancer
Karl S. Peggs, Neil H. Segal, James P. Allison  Cancer Cell 
Illuminating the Properties of Prostate Luminal Progenitors
Cutaneous Cancer Stem Cells: β-Catenin Strikes Again
Chapter 08 The T Cell Receptor: Proteins and Genes
Stress Can Be a Good Thing for Blood Formation
Cancer: Inappropriate Expression of Stem Cell Programs?
Volume 1, Issue 5, Pages (November 2007)
Engineering Static and Dynamic Control of Synthetic Pathways
Kevin G. Chen, Barbara S. Mallon, Ronald D.G. McKay, Pamela G. Robey 
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Volume 1, Issue 1, Pages (June 2007)
An Activation Marker Finds a Function
All roads lead to FoxO Cell Metabolism
Human Induced Pluripotent Stem Cells: Now Open to Discovery
A Path to Insulin Independence: “The End of the Beginning”
Surveillance for Secure Differentiation
Toll-like Receptors Keep Antigen Sorting on the Right Track
Gerry P. Crossan, Juan I. Garaycoechea, Ketan J. Patel  Cell Stem Cell 
Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Communication in Drug Development: “Translating” Scientific Discovery
Natalia J. Martinez, Richard I. Gregory  Cell Stem Cell 
Regulating Cancer Stem Cells the miR Way
Wing Y. Chang, William L. Stanford  Cell Stem Cell 
Volume 134, Issue 5, Pages (May 2008)
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Wenlian Qiao, Peter W. Zandstra  Cell Stem Cell 
Volume 17, Issue 3, Pages (September 2015)
Cutaneous Cancer Stem Cells: β-Catenin Strikes Again
Organoid Center Strategies for Accelerating Clinical Translation
Krishanu Saha, Rudolf Jaenisch  Cell Stem Cell 
Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs
Volume 18, Issue 2, Pages (February 2016)
Volume 22, Issue 6, Pages (June 2018)
Loukia Yiangou, Alexander D.B. Ross, Kim Jee Goh, Ludovic Vallier 
Direct Lineage Reprogramming: Strategies, Mechanisms, and Applications
Regenerating Eye Tissues to Preserve and Restore Vision
Lung Cancer: A Wily Genetic Opponent
Engineering Stem Cell Organoids
Systems Biology Strikes Gold
Modifying Mitochondrial tRNAs: Delivering What the Cell Needs
Targeting Cancer Stemness in the Clinic: From Hype to Hope
The Promise and Perils of Stem Cell Therapeutics
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches
The Principles of Engineering Immune Cells to Treat Cancer
Powering Reprogramming with Vitamin C
The Stem Cell Niche in Regenerative Medicine
Cancer Modeling in the Modern Era
NO Signals from the Cancer Stem Cell Niche
Volume 5, Issue 1, Pages (January 2019)
Cytokine Signaling Modules in Inflammatory Responses
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Selfish Stem Cells Compete with Each Other
The Systematic Production of Cells for Cell Therapies
Volume 12, Issue 6, Pages (December 2007)
Devyn M. Smith, Emily J. Culme-Seymour, Chris Mason  Cell Stem Cell 
Cellular Alchemy and the Golden Age of Reprogramming
Notching Up MYC Gives a LIC
Targeting Protein Stability with a Small Molecule
Presentation transcript:

Volume 20, Issue 1, Pages 13-17 (January 2017) Achieving Efficient Manufacturing and Quality Assurance through Synthetic Cell Therapy Design  Yonatan Y. Lipsitz, Patrick Bedford, Anthony H. Davies, Nicholas E. Timmins, Peter W. Zandstra  Cell Stem Cell  Volume 20, Issue 1, Pages 13-17 (January 2017) DOI: 10.1016/j.stem.2016.12.003 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Therapeutics Designed from Readily Available Cell Types Can Fail to Address Unmet Clinical Need Therapeutics may lack a needed function (the function of protein “C”) or exist in an undesirable gene regulatory network state (state “ABC”). Tools to engineering cells include gene manipulation (e.g., inserting gene “C” into the cell) or cell state manipulation (cytokine-induced shift to gene regulatory network “BCDE”). These strategies can resolve CTP challenges including designing new CTP functionality (such as a new receptor on an immune cell for a cancer-specific antigen), simplifying quality assessment by indicating or selecting for a desired cell population in a heterogeneous culture, and enhancing cell manufacturability by generating universal-donor or robustly expanding cell populations. These modifications are illustrated in red. Cell Stem Cell 2017 20, 13-17DOI: (10.1016/j.stem.2016.12.003) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 2 Complexity and Extent of Synthetic Properties of CTPs Compared to Other Therapeutics Synthetic cell therapy via cell engineering represents a logical next step to which other therapeutic types have progressed. Just as small-molecule drugs progressed from naturally occurring products through synthesized drugs to synthetic, biomaterial integrated drugs, so too have cell therapies progressed from minimally manipulated cells to cultured cells, and now to engineered cells. A key difference between these strategies is the increased complexity of engineered cells relative to small-molecule drugs and most biologics. However, ample precedent for the progression to synthetic therapeutics has been set in other advanced therapies including a variety of antibody-drug conjugates and engineered protein products. Cell Stem Cell 2017 20, 13-17DOI: (10.1016/j.stem.2016.12.003) Copyright © 2017 Elsevier Inc. Terms and Conditions